Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- ...
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with ...
India Currents on MSN
As health cuts hit nationwide, California protects full maternal care
As federal health programs face cuts, California is expanding maternal health care through Medi-Cal. The state now offers one ...
Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single clinical workflow. By ...
Dermatologists explain the science behind wildly popular treatments like red light therapy, which is now available at home—for a steep price. Full-face LED masks like this one can cost up to several ...
A team led by Professor Guosheng Tang from Guangzhou Medical University, Associate Professor Yutao Liu from Tianjin University, and Professor Bin Liu ...
Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier ...
The global clinical decision support systems market size was US$ 3.0 billion in 2021. The global clinical decision support systems market size is forecast to reach US$ 3.9 billion by 2030, growing at ...
BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...
In this report, we present an adolescent patient with a 46,XY karyotype and phenotypically female genitalia secondary to campomelic dysplasia who presented with primary amenorrhea. This patient is ...
T his past year, we explored a lot of new cell biology research—from cancer to plants to microbes, and more! It’s hard to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback